1. United Kingdom Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Creo Medical Group Plc

Creo Medical Group Plc

11.25
GBX
+0.50
(+4.65%)
4.08BMarket Cap
Jun 02Next Earn
Creo Medical Group Plc
LSE:CREO
(London Stock Exchange)

Recent

price

11.25

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
GBP
- -
- -
- -
- -
- -
- -
0.06
0.15
0.14
0.01
0.01
0.01
- -
Revenue per Share
-0.02
-0.03
-0.04
-0.12
-0.1
-0.13
-0.13
-0.14
-0.14
-0.07
-0.08
0.01
- -
Basic EPS, GAAP
-0.02
-0.03
-0.04
-0.11
-0.15
-0.1
-0.1
-0.19
-0.15
-0.07
-0.06
-0.05
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.02
0.01
0.04
0.17
- -
0.53
0.38
0.39
0.26
0.17
0.1
0.12
0.12
Book Value per Share
0.02
0.01
0.04
0.17
- -
0.52
0.21
0.25
0.12
0.09
0.1
0.12
0.12
Tangible Book Value per Share
84
84
84
62
84
126
162
170
188
313
370
412
412
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
9
25
27
4
4
6
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
-140,097.81
-249.06
-118.86
-112.87
-672.5
-720
-325
- -
Operating Margin (%)
- -
- -
- -
- -
- -
1
2
3
3
3
3
1
- -
Depreciation Expense
-2
-2
-3
-8
-8
-16
-20
-25
-27
-22
-29
5
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
-118,096.56
-215.46
-97.75
-98.9
-542.5
-717.5
88.33
- -
Profit Margin (%)
1
1
3
14
- -
81
41
41
16
28
36
16
16
Working Capital
- -
- -
- -
- -
- -
1
7
5
6
5
2
2
2
LT Debt
1
1
3
15
- -
83
63
73
49
60
42
50
50
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-224.39
-167.72
-86.89
- -
- -
-27.93
-36.14
-43.88
-39.78
-56.16
11.47
- -
Return on Common Equity (%)

Capital Structure

GBP

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
2
2
2
LT Borrowings
2
- -
2
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
412
412
412
Market Capitalization
80
55
41

Working Capital

GBP

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
56
32
24
Cash, Cash Equivalents & STI
9
21
12
Accounts Receivable, Net
1
3
5
Inventories
3
3
3
Total Current Liabilities
21
6
7
Payables & Accruals
- -
- -
- -
ST Debt
2
2
2
Deferred Revenue
- -
- -
- -

Growth Rates

GBP

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-1.18%
17.92%
Free Cash Flow
31.66%
9.31%
-11.5%
Net Income, GAAP
22.31%
-15.02%
-118.47%
Sales/Revenue/Turnover
- -
- -
50%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
4
2024
- -
- -
4
2025
- -
- -
6

Semi-annual Earnings Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.07
2024
- -
- -
-0.08
2025
- -
- -
0.01

Semi-annual Dividends Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Creo Medical Group plc Creo Medical Group plc develops, manufactures and commercialises minimally invasive electrosurgical devices for therapeutic endoscopy utilising its proprietary CROMA advanced energy platform powered by Kamaptive technology, which seamlessly integrates microwave and bipolar radiofrequency energies for precise cutting, coagulation, resection, ablation and dissection; key products include the Speedboat family of devices such as Speedboat Inject, Speedboat UltraSlim and Speedboat Notch for underwater endoscopic dissection in gastroenterology, the MicroBlate range including MicroBlate Flex and MicroBlate Fine for microwave ablation in pulmonology and oncology applications, SpydrBlade Flex for dissection, SlypSeal Flex for haemostasis, and a supporting suite of single-use and reusable endotherapy accessories in diagnostics, therapeutics and hygiene across gastroenterology, urology, pulmonology and surgery. The company serves clinicians and hospitals worldwide with operations spanning Europe, the US, Asia-Pacific including a regional hub in Singapore, and emerging markets in Latin America, Africa and India; headquartered in Chepstow, South Wales, United Kingdom, it was founded in 2003 as MicroOncology Ltd and rebranded to Creo Medical in 2010 before listing on the London Stock Exchange AIM market. Recent developments include the 2024 sale of a 51% stake in its European subsidiary Creo Medical Europe to Micro-Tech Endoscopy for balance sheet strengthening and expanded product distribution, commercial launches of Speedboat UltraSlim, SpydrBlade Flex, Speedboat Notch and Reusable Interface Cable, US FDA clearance for MicroBlate Flex, first robotically guided procedures with Intuitive Surgical collaboration, acquisition of Aber Electronics in 2021 for supply chain enhancement, and openings of US headquarters in Danbury, Connecticut and APAC hub in Singapore to support global commercialisation.